Full Breakdown
The Competitive Landscape of Weight Loss Drugs: Eli Lilly, Novo Nordisk, and Pfizer
9/25/2025, 9:20:03 PM
Market Dynamics and Key Players
The weight loss drug market is currently dominated by Eli Lilly and Novo Nordisk, with both companies reporting substantial revenues from their glucagon-like peptide-1 (GLP-1) medications. Eli Lilly's Mounjaro and Zepbound contributed $8.58 billion to its total revenue of $15.56 billion in the last quarter. Novo Nordisk, known for its insulin products, has seen a significant shift in focus since launching semaglutide, branded as Ozempic and Wegovy, which has become widely recognized for its weight management capabilities.
Pfizer's Strategic Shift
In an effort to compete, Pfizer has shifted its strategy after discontinuing research on its experimental weight loss drug, Danuglipron, due to safety concerns. The company is now pursuing a $7.3 billion acquisition of Metsera, which has several clinical-stage obesity drug candidates but lacks an approved product. Analysts project that Metsera's candidates could generate over $5 billion in peak sales, which is critical for Pfizer as it faces a "steep patent cliff" with several drugs losing patent protection by 2028.
Emerging Treatments: Orforglipron
Eli Lilly is also advancing its pipeline with orforglipron, a new oral GLP-1 receptor agonist. Recent research presented at the Annual Meeting of the European Association for the Study of Diabetes demonstrated that orforglipron resulted in significant weight loss among participants without type 2 diabetes. In a trial involving 3,127 patients across nine countries, those taking the highest dose of orforglipron experienced an average weight reduction of 11.2%, alongside improvements in various cardiometabolic markers.
Challenges for Novo Nordisk
Novo Nordisk is currently facing challenges, including a significant job cut of 9,000 positions aimed at saving DKK 8 billion annually. The company has struggled to meet the increasing demand for its obesity drugs, losing market share to Eli Lilly. The FDA's listing of semaglutide as a drug in shortage has allowed compounding pharmacies to offer alternatives, further complicating Novo's market position. Despite these setbacks, Novo remains optimistic about its drug portfolio and is exploring both oral and injectable treatments.
Criticism and Market Access Issues
The rising demand for GLP-1 medications has highlighted access issues, particularly in the UK, where many patients are unable to obtain necessary prescriptions through the National Health Service (NHS). Reports indicate that patients in certain regions, termed "fat jab deserts," face significant barriers to accessing these life-saving treatments. Experts have raised concerns about the NHS's capacity to meet the growing demand, emphasizing the need for improved infrastructure and support for obesity management.
Official Statements and Future Directions
Eli Lilly plans to file for regulatory approval of orforglipron in multiple countries, including the United States and India, where there is a growing acceptance of obesity treatments. Meanwhile, Novo Nordisk is under pressure to adapt its pricing strategies as patents for its drugs are set to expire, opening the market to generic competition. Both companies are committed to advancing their drug pipelines, with the medical community increasingly recognizing the importance of pharmacotherapy in obesity management.
Verbatim Quotes
- “This could mean an expansion of obesity interventions to groups who are currently excluded due to the cost of and lack of access to injectable medications.” — Dr. Sean Wharton, McMaster University
Conclusion
The competitive landscape of weight loss drugs is evolving rapidly, with Eli Lilly and Novo Nordisk leading the charge while Pfizer seeks to regain its footing. As new treatments emerge and market dynamics shift, the focus remains on improving access and outcomes for patients struggling with obesity.
